BB Biotech Financials
| BION Stock | CHF 36.25 0.30 0.83% |
BION |
Understanding current and past BB Biotech Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BB Biotech's financial statements are interrelated, with each one affecting the others. For example, an increase in BB Biotech's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in BB Biotech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BB Biotech AG. Check BB Biotech's Beneish M Score to see the likelihood of BB Biotech's management manipulating its earnings.
BB Biotech Stock Summary
BB Biotech competes with Santhera Pharmaceuticals, Evolva Holding, and COSMO Pharmaceuticals. BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland. BB BIOTECH operates under Pharmaceuticals And Biosciences classification in Switzerland and is traded on Switzerland Exchange.| Foreign Associate | UK |
| Instrument | Switzerland Stock View All |
| Exchange | SIX Swiss Exchange |
| ISIN | CH0038389992 |
| Business Address | Seestrasse 16, Kusnacht, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.bbbiotech.ch/en/bb-biotech/ |
| Phone | 41 44 267 67 00 |
| Currency | CHF - Swiss Franc |
You should never invest in BB Biotech without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of BION Stock, because this is throwing your money away. Analyzing the key information contained in BB Biotech's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
BB Biotech Key Financial Ratios
There are many critical financial ratios that BB Biotech's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that BB Biotech AG reports annually and quarterly.| Return On Equity | -0.26 | |||
| Return On Asset | -0.0411 | |||
| Target Price | 69.52 | |||
| Number Of Employees | 10 | |||
| Beta | 0.87 |
BION Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BB Biotech's current stock value. Our valuation model uses many indicators to compare BB Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BB Biotech competition to find correlations between indicators driving BB Biotech's intrinsic value. More Info.BB Biotech AG is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BB Biotech's earnings, one of the primary drivers of an investment's value.BB Biotech AG Systematic Risk
BB Biotech's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BB Biotech volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on BB Biotech AG correlated with the market. If Beta is less than 0 BB Biotech generally moves in the opposite direction as compared to the market. If BB Biotech Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BB Biotech AG is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BB Biotech is generally in the same direction as the market. If Beta > 1 BB Biotech moves generally in the same direction as, but more than the movement of the benchmark.
BB Biotech Thematic Clasifications
BB Biotech AG is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
BB Biotech November 23, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BB Biotech help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BB Biotech AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of BB Biotech AG based on widely used predictive technical indicators. In general, we focus on analyzing BION Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BB Biotech's daily price indicators and compare them against related drivers.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 6.87 | |||
| Value At Risk | (2.29) | |||
| Potential Upside | 1.67 |
Additional Tools for BION Stock Analysis
When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.